Spectral to Present at the SNN Network Canada Virtual Event on Wednesday, December 8, 2021
03 Dezember 2021 - 2:00PM
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:
EDT) and its wholly-owned subsidiary Dialco Medical Inc.
(“Dialco”), today announced that Chris Seto, Chief
Executive Officer of Spectral Medical, is scheduled to present at
the SNN Network Canada Virtual Event taking place on December 7-9,
2021.
Mr. Seto is scheduled to present on Wednesday,
December 8, 2021, at 9:00 A.M. Eastern Time. The event will be
broadcast live and can be accessed and replayed here.
Mr. Seto will also host one-on-one meetings with
qualified investors throughout the conference. Registration is
complimentary for qualified investors. For more information or to
register for the event, please visit canada.snn.network.
About SNN Network Canada Virtual
Event
SNN Network and Small Cap Discoveries, the
leading Canadian MicroCap newsletter, have teamed up to highlight
our neighbors to the North: Canada. Between SNN’s audience and
Small Cap Discoveries’ newsletter following, we have joined forces
to provide a platform for investors to learn about the highest
quality public micro cap companies listed on Canadian exchanges, as
well as hear from fund managers, newsletter writers and financial
influencers with experience and expertise investing in these
Canadian assets.
About Spectral
Spectral is a Phase III company seeking U.S. FDA
approval for its unique product for the treatment of patients with
septic shock, Toraymyxin™ (“PMX”). PMX is a
therapeutic hemoperfusion device that removes endotoxin, which can
cause sepsis, from the bloodstream and is guided by the Company’s
Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic
for the risk of developing sepsis.
PMX has been approved for therapeutic use in
Japan and Europe, and has been used safely and effectively on more
than 300,000 patients to date. In March 2009, Spectral obtained the
exclusive development and commercial rights in the U.S. for PMX,
and in November 2010, signed an exclusive distribution agreement
for this product in Canada. Approximately 330,000 patients are
diagnosed with severe sepsis and septic shock in North America each
year.
Spectral, through its wholly owned subsidiary,
Dialco Medical Inc., is also commercializing a new set of
proprietary platforms addressing renal replacement therapy
(“RRT”) across the dialysis spectrum. SAMI is
targeting the acute RRT market, while DIMI is targeting the chronic
RRT market. Dialco is currently pursuing regulatory approval for
U.S. in-home use of DIMI, which is based on the same RRT platform
as SAMI, but will be intended for home hemodialysis use. DIMI
recently received its FDA 510k clearance for use in hospital and
clinical settings, and obtained its Health Canada license for use
within Canadian hospitals, clinics and in home.
Spectral is listed on the Toronto Stock Exchange
under the symbol EDT. For more information, please visit
www.spectraldx.com.
Forward-looking statement
Information in this news release that is not
current or historical factual information may constitute
forward-looking information within the meaning of securities laws.
Implicit in this information, particularly in respect of the future
outlook of Spectral and anticipated events or results, are
assumptions based on beliefs of Spectral's senior management as
well as information currently available to it. While these
assumptions were considered reasonable by Spectral at the time of
preparation, they may prove to be incorrect. Readers are cautioned
that actual results are subject to a number of risks and
uncertainties, including the availability of funds and resources to
pursue R&D projects, the successful and timely completion of
clinical studies, the ability of Spectral to take advantage of
business opportunities in the biomedical industry, the granting of
necessary approvals by regulatory authorities as well as general
economic, market and business conditions, and could differ
materially from what is currently expected.
The TSX has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
Contact:
Mr. Chris Seto |
Mr. Ali Mahdavi |
David Waldman/Natalya Rudman |
CEO |
Capital Markets & Investor Relations |
US Investor Relations |
Spectral Medical Inc. |
Spinnaker Capital Markets Inc. |
Crescendo Communications, LLC |
416-626-3233 ext. 2004 |
416-962-3300 |
212-671-1020 |
cseto@spectraldx.com |
am@spinnakercmi.com |
edt@crescendo-ir.com |
Spectral Medical (TSX:EDT)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Spectral Medical (TSX:EDT)
Historical Stock Chart
Von Apr 2023 bis Apr 2024